ESSA Pharma (US:EPIX) Globenewswire·2025-03-24 09:35Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. due to alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024 [1] Group 1: Allegations of Fraud - The complaint alleges that defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, claiming it had no clear efficacy benefit over enzalutamide alone [2] - It is claimed that masofaniten in combination with enzalutamide was less effective in treating prostate cancer than previously communicated to investors [2] - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the defendants' public statements [2] - Defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2] Group 2: Legal Process and Participation - Investors who suffered losses in ESSA Pharma Inc. during the relevant timeframe have until March 25, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]